Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146274

Pw146274 View Pathway
drug action

Sodium sulfide Drug Metabolism Action Pathway

Homo sapiens

PW132208

Pw132208 View Pathway
metabolic

Sodium tartrate Drug Metabolism

Homo sapiens
Sodium tartrate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sodium tartrate passes through the liver and is then excreted from the body mainly through the kidney.

PW146668

Pw146668 View Pathway
drug action

Sodium tartrate Drug Metabolism Action Pathway

Homo sapiens

PW132282

Pw132282 View Pathway
metabolic

Sodium tetradecyl sulfate Drug Metabolism

Homo sapiens
Sodium tetradecyl sulfate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sodium tetradecyl sulfate passes through the liver and is then excreted from the body mainly through the kidney.

PW144587

Pw144587 View Pathway
drug action

Sodium tetradecyl sulfate Drug Metabolism Action Pathway

Homo sapiens

PW146743

Pw146743 View Pathway
drug action

Sodium zirconium cyclosilicate Drug Metabolism Action Pathway

Homo sapiens

PW127736

Pw127736 View Pathway
drug action

Sofosbuvir Action Pathway

Homo sapiens
Sofosbuvir is a direct-acting antiviral agent used to treat specific hepatitis C virus in combination with other anti-viral drugs Hepatitis C virus lipoviroparticles enter target hepatocytes via receptor-mediated endocytosis. The lipoviroparticles attach to LDL-R and SR-B1, and then the virus binds to CD81 and subsequently claudin-1 and occludin, which mediate the late steps of viral entry. The virus is internalized by clathrin-dependent endocytosis. RNA is released from the mature Hepatitis C virion and translated at the rough endoplasmic reticulum into a single Genome polyprotein. The genome polyprotein is cleaved by host and viral proteases into 10 viral proteins. The nucleocapsid protein core and the two envelope proteins E1 and E2 form the N terminus of the polyprotein and are the structural components of HCV virions. The precursor also gives rise to the viroporin p7 and six non-structural (NS) proteins. Sofosbuvir is an inhibitor of the Hepatitis C Virus (HCV) Nonstructural protein 5B, which is an RNA-dependent RNA polymerase. RNA polymerase is required for viral RNA replication and assembly of HCV virions. By binding to nonstructural protein 5B outside of the active site of the enzyme, dasabuvir induces a conformational change. Viral RNA replication complexes localize to lipid raft-containing, detergent-resistant membranes created by the viral protein NS4B. For full viral replication and maturation, nonstructural protein 5B is required so viral RNA replication cannot occur. Envelope glycoproteins are acquired through budding into the endoplasmic reticulum lumen. The immature, non-infective virions are released via the cellular golgi apparatus.

PW145896

Pw145896 View Pathway
drug action

Sofosbuvir Drug Metabolism Action Pathway

Homo sapiens

PW145460

Pw145460 View Pathway
drug action

Solifenacin Drug Metabolism Action Pathway

Homo sapiens

PW127978

Pw127978 View Pathway
drug action

Solifenacin M3 Bladder Muscle Relaxation Action Pathway

Homo sapiens
Solifenacin is a muscarinic antagonist with antispasmodic properties used to treat urge urinary incontinence, urgency, and urinary frequency associated with an overactive bladder. It can be found under the brand name Vesicare. It has a long duration of action as it is usually taken once daily. Solifenacin is a competitive muscarinic receptor antagonist. Solifenacin's antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder. Solifenacin works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder. As a potent and selective muscarinic receptor antagonist, solifenacin acts specifically at the M3 receptor site. Possible side effects of using solifenacin may include dry mouth, headache, dizziness, and vertigo. Solifenacine is administered as an oral tablet.